{"id":"https://openalex.org/W7125941391","doi":"https://doi.org/10.1097/cad.0000000000001810","title":"The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors","display_name":"The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors","publication_year":2026,"publication_date":"2026-01-21","ids":{"openalex":"https://openalex.org/W7125941391","doi":"https://doi.org/10.1097/cad.0000000000001810","pmid":"https://pubmed.ncbi.nlm.nih.gov/41601163"},"language":"en","primary_location":{"id":"doi:10.1097/cad.0000000000001810","doi":"https://doi.org/10.1097/cad.0000000000001810","is_oa":true,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001810","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1097/cad.0000000000001810","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5123283762","display_name":"Alexandra Paulet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Alexandra Paulet","raw_affiliation_strings":["School of Medicine and Surgery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine and Surgery","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Silvia Mancini","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Silvia Mancini","raw_affiliation_strings":["School of Medicine and Surgery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine and Surgery","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004699983","display_name":"Martina Catalano","orcid":"https://orcid.org/0000-0003-1856-2848","observed_orcids":["https://orcid.org/0000-0003-1856-2848"]},"institutions":[{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Martina Catalano","raw_affiliation_strings":["Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence","institution_ids":["https://openalex.org/I45084792"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117723305","display_name":"Kristian Shtembari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristian Shtembari","raw_affiliation_strings":["School of Medicine and Surgery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine and Surgery","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039800393","display_name":"Claudia De Angelis","orcid":"https://orcid.org/0000-0003-0398-5610","observed_orcids":["https://orcid.org/0000-0003-0398-5610"]},"institutions":[{"id":"https://openalex.org/I4210115393","display_name":"Azienda Ospedaliero-Universitaria Careggi","ror":"https://ror.org/02crev113","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210115393"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Claudia De Angelis","raw_affiliation_strings":["Clinical Oncology, Careggi University Hospital, Florence"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Oncology, Careggi University Hospital, Florence","institution_ids":["https://openalex.org/I4210115393"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047413929","display_name":"Roberto Petrioli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I102064193","display_name":"University of Siena","ror":"https://ror.org/01tevnk56","country_code":"IT","type":"education","lineage":["https://openalex.org/I102064193"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Roberto Petrioli","raw_affiliation_strings":["Unit of Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unit of Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy","institution_ids":["https://openalex.org/I102064193"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020078965","display_name":"Daniele Generali","orcid":"https://orcid.org/0000-0003-2480-3855","observed_orcids":["https://orcid.org/0000-0003-2480-3855"]},"institutions":[{"id":"https://openalex.org/I142444530","display_name":"University of Trieste","ror":"https://ror.org/02n742c10","country_code":"IT","type":"education","lineage":["https://openalex.org/I142444530"]},{"id":"https://openalex.org/I4210165579","display_name":"Istituti Ospitalieri di Cremona","ror":"https://ror.org/05w07vs91","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210165579"]},{"id":"https://openalex.org/I4396570609","display_name":"Azienda Socio Sanitaria Territoriale di Cremona","ror":"https://ror.org/02h6t3w06","country_code":"IT","type":"government","lineage":["https://openalex.org/I4396570609"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Daniele Generali","raw_affiliation_strings":["Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste","Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste","institution_ids":["https://openalex.org/I142444530"]},{"raw_affiliation_string":"Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy","institution_ids":["https://openalex.org/I4210165579","https://openalex.org/I4396570609"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037756908","display_name":"Giandomenico Roviello","orcid":"https://orcid.org/0000-0001-5504-8237","observed_orcids":["https://orcid.org/0000-0001-5504-8237","https://orcid.org/0000-0002-5185-6701"]},"institutions":[{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giandomenico Roviello","raw_affiliation_strings":["Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence","institution_ids":["https://openalex.org/I45084792"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5123283762"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.5575,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.83345809,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"37","issue":"8","first_page":"512","last_page":"521"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/hormone-receptor-positive-her2-negative-metastatic-breast-cancer","display_name":"hormone receptor-positive HER2-negative metastatic breast cancer","score":0.9190000295639038},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.984000027179718},{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":1.0},{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":1.0},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7170000076293945},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9599999785423279},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.5879999995231628},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.777999997138977},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/pulmonary-toxicity","display_name":"pulmonary toxicity","score":0.7519999742507935},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.7599999904632568},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.6140000224113464},{"id":"https://openalex.org/keywords/toxicity-management","display_name":"toxicity management","score":0.699999988079071}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8835999965667725},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.8039000034332275},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7261000275611877},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6171000003814697},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5831000208854675},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5777999758720398},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5673999786376953},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4848000109195709},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.4699999988079071},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.4544999897480011},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.40450000762939453},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.3783000111579895},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.3684999942779541},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.357699990272522},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.3538999855518341},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3490999937057495},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3084999918937683},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.3019999861717224},{"id":"https://openalex.org/C2777793932","wikidata":"https://www.wikidata.org/wiki/Q1116229","display_name":"Common Terminology Criteria for Adverse Events","level":3,"score":0.2849999964237213},{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.28380000591278076},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.28349998593330383},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.2768999934196472},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2648000121116638},{"id":"https://openalex.org/C46699223","wikidata":"https://www.wikidata.org/wiki/Q11078","display_name":"Endocrine system","level":3,"score":0.2639000117778778},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.2572999894618988},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.2556999921798706},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.25450000166893005}],"mesh":[{"descriptor_ui":"D000077982","descriptor_name":"Progression-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D051358","descriptor_name":"Cyclin-Dependent Kinase 4","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051361","descriptor_name":"Cyclin-Dependent Kinase 6","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1097/cad.0000000000001810","doi":"https://doi.org/10.1097/cad.0000000000001810","is_oa":true,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001810","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:41601163","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41601163","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Journal Article"},{"id":"pmh:oai:flore.unifi.it:2158/1452124","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/2158/1452124","pdf_url":null,"source":{"id":"https://openalex.org/S4306402033","display_name":"Florence Research (University of Florence)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I45084792","host_organization_name":"University of Florence","host_organization_lineage":["https://openalex.org/I45084792"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1097/cad.0000000000001810","doi":"https://doi.org/10.1097/cad.0000000000001810","is_oa":true,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001810","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1464936406","https://openalex.org/W1967114867","https://openalex.org/W1991601194","https://openalex.org/W2019607817","https://openalex.org/W2188229458","https://openalex.org/W2290950904","https://openalex.org/W2528767298","https://openalex.org/W2552099557","https://openalex.org/W2763875663","https://openalex.org/W2787553551","https://openalex.org/W2792040629","https://openalex.org/W2804105316","https://openalex.org/W2805575723","https://openalex.org/W2976415870","https://openalex.org/W3207557929","https://openalex.org/W4206662285","https://openalex.org/W4400800926","https://openalex.org/W4407294081","https://openalex.org/W4409253861"],"related_works":["https://openalex.org/W4415151984","https://openalex.org/W4229443358","https://openalex.org/W6921351972","https://openalex.org/W7213286916","https://openalex.org/W4317470309","https://openalex.org/W4409890915","https://openalex.org/W4401813121","https://openalex.org/W7160509491","https://openalex.org/W7161979367","https://openalex.org/W7220700474"],"abstract_inverted_index":{"Cyclin-dependent":[0],"kinase":[1],"4/6":[2],"inhibitors":[3],"(CDK4/6i)":[4],"in":[5,86,112,118,153],"combination":[6],"with":[7,48,52,97,107,140,167],"endocrine":[8],"therapy":[9],"represent":[10],"the":[11,92,207],"standard":[12],"of":[13,88,114,134,157,209],"care":[14],"for":[15],"hormone":[16],"receptor-positive":[17],"(HR+),":[18],"HER2-negative":[19],"metastatic":[20],"breast":[21],"cancer":[22],"(mBC).":[23],"While":[24],"clinical":[25],"trials":[26],"established":[27],"their":[28],"efficacy,":[29],"real-world":[30,179],"evidence":[31],"on":[32,66],"safety,":[33],"dose":[34,69,192],"adjustments,":[35],"and":[36,63,74,80,99,103,124,128,170,190],"outcomes":[37],"remains":[38],"limited.":[39],"We":[40],"conducted":[41],"a":[42],"prospective":[43],"observational":[44],"study":[45],"including":[46],"patients":[47],"HR+/HER2-":[49],"mBC":[50],"treated":[51],"palbociclib,":[53],"ribociclib,":[54,100],"or":[55],"abemaciclib":[56],"across":[57],"three":[58],"oncology":[59],"units":[60],"between":[61],"2019":[62],"2024.":[64],"Data":[65],"adverse":[67,95,137],"events,":[68],"modifications,":[70],"progression-free":[71],"survival":[72,76],"(PFS),":[73],"overall":[75],"(OS)":[77],"were":[78,84,126,165],"collected":[79],"analyzed.":[81],"Adverse":[82],"events":[83,138],"reported":[85],"77.5%":[87],"patients.":[89],"Neutropenia":[90],"was":[91],"most":[93],"frequent":[94,184],"event":[96],"palbociclib":[98],"while":[101],"diarrhea":[102],"hepatic":[104],"toxicity":[105,110,188],"predominated":[106],"abemaciclib.":[108],"Pulmonary":[109],"occurred":[111],"19.1%":[113],"abemaciclib-treated":[115],"patients,":[116,158],"often":[117],"those":[119],"previously":[120],"irradiated.":[121],"Median":[122],"PFS":[123,169],"OS":[125,142],"26.4":[127],"31.1":[129],"months,":[130,146],"respectively.":[131],"The":[132],"occurrence":[133],"grade":[135],"3-4":[136],"correlated":[139],"improved":[141],"(37.1":[143],"vs.":[144],"23.0":[145],"P":[147],"<":[148],"0.001).":[149],"Dose":[150,200],"reductions,":[151],"required":[152],"more":[154],"than":[155],"60%":[156],"did":[159],"not":[160],"compromise":[161],"efficacy;":[162],"instead,":[163],"they":[164],"associated":[166],"longer":[168],"OS.":[171],"Conversely,":[172],"treatment":[173,198],"discontinuation":[174],"predicted":[175],"worse":[176],"outcomes.":[177],"In":[178],"practice,":[180],"CDK4/6i":[181],"toxicities":[182],"are":[183,194],"but":[185],"manageable.":[186],"Proactive":[187],"management":[189],"timely":[191],"adjustments":[193],"essential":[195],"to":[196],"sustain":[197],"benefit.":[199],"reductions":[201],"may":[202],"even":[203],"improve":[204],"outcomes,":[205],"underscoring":[206],"value":[208],"individualized":[210],"dosing":[211],"strategies.":[212]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2026-01-29T00:00:00"}